Hytrin (Terazosin Hydrochloride Dihydrate)

Terazosin selectively blocks post‑synaptic α1‑adrenergic receptors on vascular smooth muscle and in the prostate. This antagonism prevents norepinephrine‑induced contraction, causing vasodilation that reduces peripheral resistance and relaxing prostate and bladder neck muscles, which eases urinary obstruction.

The appropriate dose of Hytrin is individualized by a qualified prescriber based on the patient’s medical condition, response, and tolerance. Dosage adjustments are typically made gradually, starting with a low dose and titrating upward as needed to achieve therapeutic goals.

Hytrin is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It should be used during pregnancy only if the potential benefit justifies any potential risk to the fetus. Caution is also advised when breastfeeding, as the drug may pass into milk.

To order Hytrin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Hytrin (terazosin) shares the core mechanism of α1‑adrenergic blockade with other agents such as prazosin and doxazosin. Compared with some alternatives, terazosin has a relatively long half‑life, allowing once‑daily dosing in many patients, and it is approved for both hypertension and BPH, whereas some α‑blockers are indicated for only one of these conditions.

Hytrin tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, excessive heat and direct sunlight to maintain potency throughout its shelf life.

Hytrin is taken orally, usually with a full glass of water. It can be taken with or without food, but patients are advised to follow the prescriber’s instructions regarding timing, especially when initiating therapy, to reduce the risk of orthostatic dizziness.

The most serious risks include severe hypotension that can lead to syncope or shock, allergic reactions such as rash or angioedema, and rare events like priapism. Patients should seek immediate medical attention if they experience fainting, a painful prolonged erection, or signs of a severe allergic response.

Hytrin should be avoided in patients with known hypersensitivity to terazosin or any component of the formulation, in individuals with severe hepatic impairment without dose adjustment, and in patients who are already taking multiple α‑blockers or potent CYP3A4 inhibitors that could cause dangerous blood pressure drops.